4.6 Review

Production Options for Psilocybin: Making of the Magic

期刊

CHEMISTRY-A EUROPEAN JOURNAL
卷 25, 期 4, 页码 897-903

出版社

WILEY-V C H VERLAG GMBH
DOI: 10.1002/chem.201802758

关键词

biosynthesis; biotechnology; depression; natural products; psilocybin

资金

  1. International Leibniz Research School (ILRS) for Microbial Interactions
  2. Deutsche Forschungsgemeinschaft (DFG) [HO2515/7-1]
  3. Collaborative Research Center ChemBioSys [SFB1127]
  4. excellence graduate school Jena School for Microbial Communication (JSMC)

向作者/读者索取更多资源

The fungal genus Psilocybe and other genera comprise numerous mushroom species that biosynthesize psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine). It represents the prodrug to its dephosphorylated psychotropic analogue, psilocin. The colloquial term magic mushrooms for these fungi alludes to their hallucinogenic effects and to their use as recreational drugs. However, clinical trials have recognized psilocybin as a valuable candidate to be developed into a medication against depression and anxiety. We here highlight its recently elucidated biosynthesis, the concurrently developed concept of enzymatic in vitro and heterologous in vivo production, along with previous synthetic routes. The prospect of psilocybin as a promising therapeutic may entail an increased demand, which can be met by biotechnological production. Therefore, we also briefly touch on psilocybin's therapeutic relevance and pharmacology.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据